EP3294345A4 - Formulations de tpp1 et méthodes de traitement de la maladie cln2 - Google Patents

Formulations de tpp1 et méthodes de traitement de la maladie cln2 Download PDF

Info

Publication number: EP3294345A4
Authority: EP; European Patent Office
Prior art keywords: tpp1; formulations; methods; cln2 disease; treating cln2
Prior art date: 2015-05-08
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

EP16793229.2A

Other languages

German (de)

English (en)

Other versions

EP3294345A1 (fr

EP3294345B1 (fr

Inventor

Thomas W. LESTER

Saeed Moshashaee

Augustus O. Okhamafe

Charles A. O'NEILL

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Biomarin Pharmaceutical Inc

Original Assignee

Biomarin Pharmaceutical Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-05-08

Filing date

2016-05-05

Publication date

2019-01-16

2016-05-05 Application filed by Biomarin Pharmaceutical Inc filed Critical Biomarin Pharmaceutical Inc

2016-05-05 Priority to SI201631792T priority Critical patent/SI3294345T1/sl

2016-05-05 Priority to RS20240067A priority patent/RS65101B1/sr

2016-05-05 Priority to SM20240026T priority patent/SMT202400026T1/it

2016-05-05 Priority to EP23204139.2A priority patent/EP4327873A3/fr

2016-05-05 Priority to HRP20240050TT priority patent/HRP20240050T1/hr

2018-03-21 Publication of EP3294345A1 publication Critical patent/EP3294345A1/fr

2019-01-16 Publication of EP3294345A4 publication Critical patent/EP3294345A4/fr

2023-10-18 Application granted granted Critical

2023-10-18 Publication of EP3294345B1 publication Critical patent/EP3294345B1/fr

Status Active legal-status Critical Current

2036-05-05 Anticipated expiration legal-status Critical

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/485—Exopeptidases (3.4.11-3.4.19)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/14—Dipeptidyl-peptidases and tripeptidyl-peptidases (3.4.14)
- C12Y304/14009—Tripeptidyl-peptidase I (3.4.14.9)
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Biomedical Technology (AREA)
Organic Chemistry (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Zoology (AREA)
Genetics & Genomics (AREA)
Wood Science & Technology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Psychology (AREA)
Orthopedic Medicine & Surgery (AREA)
Ophthalmology & Optometry (AREA)
Molecular Biology (AREA)
Inorganic Chemistry (AREA)
Biotechnology (AREA)
Microbiology (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)
Anesthesiology (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)

EP16793229.2A 2015-05-08 2016-05-05 Formulations de tpp1 et méthodes de traitement de la maladie cln2 Active EP3294345B1 (fr)

Priority Applications (5)

Application Number	Priority Date	Filing Date	Title
SI201631792T SI3294345T1 (sl)	2015-05-08	2016-05-05	Formulacije tpp1 in postopki za zdravljenje bolezni cln2
RS20240067A RS65101B1 (sr)	2015-05-08	2016-05-05	Tpp1 formulacije i postupci za lečenje cln2 bolesti
SM20240026T SMT202400026T1 (it)	2015-05-08	2016-05-05	Formulazioni di tpp1 e metodi per trattare la malattia cln2
EP23204139.2A EP4327873A3 (fr)	2015-05-08	2016-05-05	Formulations de tpp1 et méthodes de traitement de la maladie cln2
HRP20240050TT HRP20240050T1 (hr)	2015-05-08	2016-05-05	Formulacije tpp1 i postupci liječenja bolesti cln2

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201562158789P	2015-05-08	2015-05-08
US201662300171P	2016-02-26	2016-02-26
PCT/US2016/031074 WO2016182862A1 (fr)	2015-05-08	2016-05-05	Formulations de tpp1 et méthodes de traitement de la maladie cln2

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
EP23204139.2A Division EP4327873A3 (fr)	2015-05-08	2016-05-05	Formulations de tpp1 et méthodes de traitement de la maladie cln2

Publications (3)

Publication Number	Publication Date
EP3294345A1 EP3294345A1 (fr)	2018-03-21
EP3294345A4 true EP3294345A4 (fr)	2019-01-16
EP3294345B1 EP3294345B1 (fr)	2023-10-18

Family

ID=57222195

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
EP16793229.2A Active EP3294345B1 (fr)	2015-05-08	2016-05-05	Formulations de tpp1 et méthodes de traitement de la maladie cln2
EP23204139.2A Pending EP4327873A3 (fr)	2015-05-08	2016-05-05	Formulations de tpp1 et méthodes de traitement de la maladie cln2

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
EP23204139.2A Pending EP4327873A3 (fr)	2015-05-08	2016-05-05	Formulations de tpp1 et méthodes de traitement de la maladie cln2

Country Status (25)

Country	Link
US (3)	US10279015B2 (fr)
EP (2)	EP3294345B1 (fr)
JP (3)	JP6931330B2 (fr)
KR (1)	KR102375051B1 (fr)
CN (2)	CN107847615B (fr)
AU (1)	AU2016262434B2 (fr)
CA (1)	CA2984448A1 (fr)
CL (1)	CL2017002825A1 (fr)
DK (1)	DK3294345T3 (fr)
ES (1)	ES2968375T3 (fr)
FI (1)	FI3294345T3 (fr)
HR (2)	HRP20240050T1 (fr)
HU (1)	HUE065649T2 (fr)
IL (3)	IL299024B2 (fr)
LT (1)	LT3294345T (fr)
MX (1)	MX2017014204A (fr)
PL (1)	PL3294345T3 (fr)
PT (1)	PT3294345T (fr)
RS (1)	RS65101B1 (fr)
RU (1)	RU2733464C2 (fr)
SI (1)	SI3294345T1 (fr)
SM (1)	SMT202400026T1 (fr)
TW (1)	TWI752907B (fr)
WO (1)	WO2016182862A1 (fr)
ZA (1)	ZA201707373B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI752907B (zh) *	2015-05-08	2022-01-21	美商拜奧馬林製藥公司	用於治療cln2疾病之tpp1調配物及方法
EP3607320A4 (fr)	2017-04-03	2021-04-21	The Regents of the University of California	Compositions et procédés de diagnostic du cancer du pancréas
WO2019060298A1 (fr)	2017-09-19	2019-03-28	Neuroenhancement Lab, LLC	Procédé et appareil de neuro-activation
US11717686B2 (en)	2017-12-04	2023-08-08	Neuroenhancement Lab, LLC	Method and apparatus for neuroenhancement to facilitate learning and performance
US11318277B2 (en)	2017-12-31	2022-05-03	Neuroenhancement Lab, LLC	Method and apparatus for neuroenhancement to enhance emotional response
US12280219B2 (en)	2017-12-31	2025-04-22	NeuroLight, Inc.	Method and apparatus for neuroenhancement to enhance emotional response
US11364361B2 (en)	2018-04-20	2022-06-21	Neuroenhancement Lab, LLC	System and method for inducing sleep by transplanting mental states
CN113382683A (zh)	2018-09-14	2021-09-10	纽罗因恒思蒙特实验有限责任公司	改善睡眠的系统和方法
IL327339A (en) *	2018-11-14	2026-05-01	Regenxbio Inc	Gene therapy for neural ceroid lipofuscinosis
US11786694B2 (en)	2019-05-24	2023-10-17	NeuroLight, Inc.	Device, method, and app for facilitating sleep
US20220381784A1 (en) *	2019-06-07	2022-12-01	The Regents Of The University Of California	Systems comprising substrates and methods of using the same for detection of pancreatic cancers
CN114828960A (zh) *	2019-08-29	2022-07-29	生物马林药物股份有限公司	治疗儿童个体的cln2病的方法
IT201900023142A1 (it) *	2019-12-05	2021-06-05	Sifi Spa	Composizione topica oculare contenente metaboliti della fermentazione di lactobacillus
US20230060797A1 (en) *	2021-09-02	2023-03-02	Jcr Pharmaceuticals Co., Ltd.	Therapeutic compound for neuronal ceroid lipofuscinosis
CN117731312A (zh)	2022-09-13	2024-03-22	上海联影医疗科技股份有限公司	一种医学图像的扫描方法和系统

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20100210604A1 (en) *	2007-06-13	2010-08-19	Meythaler Jay M	Zwitterion solution for low-volume therapeutic delivery
EP2333074A1 (fr) *	2009-12-14	2011-06-15	Robert Steinfeld	Substances et procédés pour le traitement de maladies liées au stockage lysosomal
WO2014085621A1 (fr) *	2012-11-27	2014-06-05	Biomarin Pharmaceutical Inc.	Protéines hybrides d'enzyme lysosomale thérapeutiques ciblées et leurs utilisations

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6302685B1 (en)	1997-09-16	2001-10-16	University Of Medicine And Dentistry Of New Jersey	Human lysosomal protein and methods of its use
US20020006400A1 (en)	2000-05-11	2002-01-17	Peter Lobel	Recombinant human CLN2 protein and methods of its production and use
SK14102003A3 (sk) *	2001-05-18	2004-08-03	Solvay Pharmaceuticals Gmbh	Použitie zlúčenín s kombinovanou inhibičnou aktivitou k NEP/MP pri príprave liečiv
AU2002362436A1 (en) *	2001-10-03	2003-04-14	Rigel Pharmaceuticals, Inc.	Modulators of lymphocyte activation and migration
CA2388659A1 (fr) *	2002-05-31	2003-11-30	Mcgill University	Expression et activite de la phospholipase a2 et utilisation de celle-ci dans le diagnostic, le pronostic, la prevention et le traitement de maladies demyelinisantes ou inflammatoires du systeme nerveux
US7442372B2 (en)	2003-08-29	2008-10-28	Biomarin Pharmaceutical Inc.	Delivery of therapeutic compounds to the brain and other tissues
US20110166074A1 (en) *	2006-10-18	2011-07-07	Cornell Research Foundation, Inc.	Cln2 treatment of alzheimer's disease
WO2012015910A2 (fr) *	2010-07-28	2012-02-02	Allon Therapeutics Inc.	Utilisation de polypeptides adnf pour traitement de maladies neurodégénératives
WO2012177929A2 (fr) *	2011-06-24	2012-12-27	Amylin Pharmaceuticals, Inc.	Procédés pour traiter le diabète avec des formulations à libération prolongée d'agonistes de procédé glp-1
US20150000936A1 (en) *	2011-12-13	2015-01-01	Schlumberger Technology Corporation	Energization of an element with a thermally expandable material
WO2013096899A2 (fr)	2011-12-23	2013-06-27	Shire Human Genetic Therapies, Inc.	Formulations stables pour l'administration au système nerveux central d'arylsulfatase a
WO2014089449A1 (fr) *	2012-12-07	2014-06-12	Rush University Nedical Center	Composition et procédé pour le traitement de céroïde-lipofuscinose neuronale
PT3024497T (pt) *	2013-07-26	2021-08-23	Univ Iowa Res Found	Métodos e composições para o tratamento de doenças cerebrais
TWI752907B (zh)	2015-05-08	2022-01-21	美商拜奧馬林製藥公司	用於治療cln2疾病之tpp1調配物及方法

2016
- 2016-04-27 TW TW105113155A patent/TWI752907B/zh active
- 2016-05-05 EP EP16793229.2A patent/EP3294345B1/fr active Active
- 2016-05-05 WO PCT/US2016/031074 patent/WO2016182862A1/fr not_active Ceased
- 2016-05-05 CN CN201680025984.6A patent/CN107847615B/zh active Active
- 2016-05-05 SM SM20240026T patent/SMT202400026T1/it unknown
- 2016-05-05 KR KR1020177032973A patent/KR102375051B1/ko active Active
- 2016-05-05 IL IL299024A patent/IL299024B2/en unknown
- 2016-05-05 CN CN202210014711.9A patent/CN114225018A/zh active Pending
- 2016-05-05 CA CA2984448A patent/CA2984448A1/fr active Pending
- 2016-05-05 MX MX2017014204A patent/MX2017014204A/es unknown
- 2016-05-05 RS RS20240067A patent/RS65101B1/sr unknown
- 2016-05-05 LT LTEPPCT/US2016/031074T patent/LT3294345T/lt unknown
- 2016-05-05 JP JP2017558434A patent/JP6931330B2/ja active Active
- 2016-05-05 US US15/147,485 patent/US10279015B2/en active Active
- 2016-05-05 ES ES16793229T patent/ES2968375T3/es active Active
- 2016-05-05 PT PT167932292T patent/PT3294345T/pt unknown
- 2016-05-05 RU RU2017142727A patent/RU2733464C2/ru active
- 2016-05-05 FI FIEP16793229.2T patent/FI3294345T3/fi active
- 2016-05-05 SI SI201631792T patent/SI3294345T1/sl unknown
- 2016-05-05 HU HUE16793229A patent/HUE065649T2/hu unknown
- 2016-05-05 HR HRP20240050TT patent/HRP20240050T1/hr unknown
- 2016-05-05 PL PL16793229.2T patent/PL3294345T3/pl unknown
- 2016-05-05 AU AU2016262434A patent/AU2016262434B2/en active Active
- 2016-05-05 DK DK16793229.2T patent/DK3294345T3/da active
- 2016-05-05 EP EP23204139.2A patent/EP4327873A3/fr active Pending
- 2016-05-05 HR HRP20171905AA patent/HRP20171905B1/hr active IP Right Grant
2017
- 2017-10-29 IL IL255307A patent/IL255307B/en active IP Right Grant
- 2017-10-30 ZA ZA2017/07373A patent/ZA201707373B/en unknown
- 2017-11-08 CL CL2017002825A patent/CL2017002825A1/es unknown
2019
- 2019-03-28 US US16/368,091 patent/US10758598B2/en active Active
2020
- 2020-04-12 IL IL273913A patent/IL273913B2/en unknown
- 2020-07-28 US US16/941,454 patent/US11229687B2/en active Active
2021
- 2021-08-13 JP JP2021131875A patent/JP7421520B2/ja active Active
2024
- 2024-01-12 JP JP2024003133A patent/JP2024026739A/ja active Pending

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20100210604A1 (en) *	2007-06-13	2010-08-19	Meythaler Jay M	Zwitterion solution for low-volume therapeutic delivery
EP2333074A1 (fr) *	2009-12-14	2011-06-15	Robert Steinfeld	Substances et procédés pour le traitement de maladies liées au stockage lysosomal
WO2014085621A1 (fr) *	2012-11-27	2014-06-05	Biomarin Pharmaceutical Inc.	Protéines hybrides d'enzyme lysosomale thérapeutiques ciblées et leurs utilisations

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BRIAN R VUILLEMENOT ET AL: "Intrathecal tripeptidyl-peptidase 1 reduces lysosomal storage in a canine model of late infantile neuronal ceroid lipofuscinosis", MOLECULAR GENETICS AND METABOLISM, ACADEMIC PRESS, AMSTERDAM, NL, vol. 104, no. 3, 23 June 2011 (2011-06-23), pages 325 - 337, XP028328996, ISSN: 1096-7192, [retrieved on 20110630], DOI: 10.1016/J.YMGME.2011.06.018 *

Also Published As

Publication number	Publication date
US20160324942A1 (en)	2016-11-10
US20190216905A1 (en)	2019-07-18
EP4327873A2 (fr)	2024-02-28
AU2016262434A1 (en)	2017-11-16
IL255307A0 (en)	2017-12-31
SMT202400026T1 (it)	2024-03-13
BR112017023805A2 (pt)	2018-07-31
LT3294345T (lt)	2024-02-12
ZA201707373B (en)	2019-02-27
JP7421520B2 (ja)	2024-01-24
TW201704469A (zh)	2017-02-01
HRP20171905B1 (hr)	2023-03-17
HK1250479A1 (en)	2018-12-21
IL299024B2 (en)	2025-12-01
IL299024B1 (en)	2025-08-01
US11229687B2 (en)	2022-01-25
WO2016182862A1 (fr)	2016-11-17
CN107847615B (zh)	2022-01-25
JP6931330B2 (ja)	2021-09-01
ES2968375T3 (es)	2024-05-09
KR102375051B1 (ko)	2022-03-15
CA2984448A1 (fr)	2016-11-17
FI3294345T3 (fi)	2024-01-15
PT3294345T (pt)	2024-01-18
US10279015B2 (en)	2019-05-07
EP4327873A3 (fr)	2024-05-01
DK3294345T3 (da)	2024-01-22
PL3294345T3 (pl)	2024-07-01
RS65101B1 (sr)	2024-02-29
HUE065649T2 (hu)	2024-06-28
SI3294345T1 (sl)	2024-03-29
US10758598B2 (en)	2020-09-01
IL299024A (en)	2023-02-01
CN114225018A (zh)	2022-03-25
HRP20240050T1 (hr)	2024-03-29
JP2021175760A (ja)	2021-11-04
RU2017142727A3 (fr)	2019-12-11
EP3294345A1 (fr)	2018-03-21
IL255307B (en)	2021-03-25
AU2016262434B2 (en)	2022-06-02
CN107847615A (zh)	2018-03-27
JP2024026739A (ja)	2024-02-28
JP2018521964A (ja)	2018-08-09
US20200353059A1 (en)	2020-11-12
TWI752907B (zh)	2022-01-21
KR20180004158A (ko)	2018-01-10
EP3294345B1 (fr)	2023-10-18
RU2017142727A (ru)	2019-06-10
RU2733464C2 (ru)	2020-10-01
CL2017002825A1 (es)	2018-06-22
IL273913A (en)	2020-05-31
HRP20171905A2 (hr)	2018-05-18
IL273913B2 (en)	2023-06-01
MX2017014204A (es)	2018-07-06

Legal Events

Date	Code	Title	Description
2016-05-05	REG	Reference to a national code	Ref country code: HR Ref legal event code: TUEP Ref document number: P20240050T Country of ref document: HR
2016-11-18	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE
2018-02-16	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2018-02-16	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE
2018-03-21	17P	Request for examination filed	Effective date: 20171208
2018-03-21	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2018-03-21	AX	Request for extension of the european patent	Extension state: BA ME
2018-08-15	DAV	Request for validation of the european patent (deleted)
2018-08-15	DAX	Request for extension of the european patent (deleted)
2018-12-21	REG	Reference to a national code	Ref country code: HK Ref legal event code: DE Ref document number: 1250479 Country of ref document: HK
2019-01-16	A4	Supplementary search report drawn up and despatched	Effective date: 20181219
2019-01-16	RIC1	Information provided on ipc code assigned before grant	Ipc: A61P 25/28 20060101ALI20181213BHEP Ipc: A61K 49/14 20060101ALI20181213BHEP Ipc: A61K 48/00 20060101ALI20181213BHEP Ipc: A61K 9/08 20060101AFI20181213BHEP
2022-06-23	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2022-07-27	17Q	First examination report despatched	Effective date: 20220622
2023-05-07	GRAP	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOSNIGR1
2023-05-07	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: GRANT OF PATENT IS INTENDED
2023-05-31	INTG	Intention to grant announced	Effective date: 20230508
2023-06-21	P01	Opt-out of the competence of the unified patent court (upc) registered	Effective date: 20230515
2023-09-08	GRAS	Grant fee paid	Free format text: ORIGINAL CODE: EPIDOSNIGR3
2023-09-15	GRAA	(expected) grant	Free format text: ORIGINAL CODE: 0009210
2023-09-15	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE PATENT HAS BEEN GRANTED
2023-10-18	AK	Designated contracting states	Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2023-10-18	REG	Reference to a national code	Ref country code: GB Ref legal event code: FG4D
2023-10-31	REG	Reference to a national code	Ref country code: CH Ref legal event code: EP
2023-11-02	REG	Reference to a national code	Ref country code: DE Ref legal event code: R096 Ref document number: 602016083547 Country of ref document: DE
2023-11-08	REG	Reference to a national code	Ref country code: IE Ref legal event code: FG4D
2024-01-15	REG	Reference to a national code	Ref country code: FI Ref legal event code: FGE
2024-01-18	REG	Reference to a national code	Ref country code: PT Ref legal event code: SC4A Ref document number: 3294345 Country of ref document: PT Date of ref document: 20240118 Kind code of ref document: T Free format text: AVAILABILITY OF NATIONAL TRANSLATION Effective date: 20240112
2024-01-22	REG	Reference to a national code	Ref country code: DK Ref legal event code: T3 Effective date: 20240119
2024-01-29	REG	Reference to a national code	Ref country code: NO Ref legal event code: T2 Effective date: 20231018
2024-01-31	REG	Reference to a national code	Ref country code: NL Ref legal event code: FP
2024-02-06	REG	Reference to a national code	Ref country code: SE Ref legal event code: TRGR
2024-02-14	REG	Reference to a national code	Ref country code: GR Ref legal event code: EP Ref document number: 20240400130 Country of ref document: GR Effective date: 20240209
2024-03-29	REG	Reference to a national code	Ref country code: HR Ref legal event code: T1PR Ref document number: P20240050 Country of ref document: HR
2024-04-10	REG	Reference to a national code	Ref country code: SK Ref legal event code: T3 Ref document number: E 43583 Country of ref document: SK
2024-04-15	REG	Reference to a national code	Ref country code: EE Ref legal event code: FG4A Ref document number: E023964 Country of ref document: EE Effective date: 20240118
2024-05-09	REG	Reference to a national code	Ref country code: ES Ref legal event code: FG2A Ref document number: 2968375 Country of ref document: ES Kind code of ref document: T3 Effective date: 20240509
2024-05-10	REG	Reference to a national code	Ref country code: HR Ref legal event code: ODRP Ref document number: P20240050 Country of ref document: HR Payment date: 20240424 Year of fee payment: 9
2024-06-28	REG	Reference to a national code	Ref country code: HU Ref legal event code: AG4A Ref document number: E065649 Country of ref document: HU
2024-07-19	REG	Reference to a national code	Ref country code: DE Ref legal event code: R097 Ref document number: 602016083547 Country of ref document: DE
2024-08-22	PLBE	No opposition filed within time limit	Free format text: ORIGINAL CODE: 0009261
2024-08-22	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT
2024-09-25	26N	No opposition filed	Effective date: 20240719
2025-05-15	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: NL Payment date: 20250423 Year of fee payment: 10
2025-05-19	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: LU Payment date: 20250423 Year of fee payment: 10
2025-05-23	REG	Reference to a national code	Ref country code: HR Ref legal event code: ODRP Ref document number: P20240050 Country of ref document: HR Payment date: 20250428 Year of fee payment: 10
2025-07-03	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: SM Payment date: 20250424 Year of fee payment: 10
2025-07-07	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: MC Payment date: 20250429 Year of fee payment: 10
2025-07-08	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: FI Payment date: 20250423 Year of fee payment: 10
2025-07-09	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: PL Payment date: 20250429 Year of fee payment: 10 Ref country code: DE Payment date: 20250423 Year of fee payment: 10
2025-07-10	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: DK Payment date: 20250423 Year of fee payment: 10 Ref country code: GB Payment date: 20250423 Year of fee payment: 10 Ref country code: ES Payment date: 20250602 Year of fee payment: 10
2025-07-11	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: LT Payment date: 20250423 Year of fee payment: 10
2025-07-14	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: IS Payment date: 20250505 Year of fee payment: 10 Ref country code: RS Payment date: 20250429 Year of fee payment: 10 Ref country code: HU Payment date: 20250515 Year of fee payment: 10 Ref country code: NO Payment date: 20250424 Year of fee payment: 10
2025-07-15	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: AL Payment date: 20250527 Year of fee payment: 10 Ref country code: BE Payment date: 20250423 Year of fee payment: 10 Ref country code: IT Payment date: 20250423 Year of fee payment: 10
2025-07-16	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: HR Payment date: 20250428 Year of fee payment: 10
2025-07-17	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: PT Payment date: 20250423 Year of fee payment: 10 Ref country code: LV Payment date: 20250423 Year of fee payment: 10
2025-07-18	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: FR Payment date: 20250423 Year of fee payment: 10 Ref country code: EE Payment date: 20250429 Year of fee payment: 10
2025-07-21	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: MT Payment date: 20250506 Year of fee payment: 10 Ref country code: BG Payment date: 20250429 Year of fee payment: 10 Ref country code: GR Payment date: 20250424 Year of fee payment: 10
2025-07-23	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: CH Payment date: 20250601 Year of fee payment: 10
2025-07-24	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: AT Payment date: 20250424 Year of fee payment: 10 Ref country code: RO Payment date: 20250505 Year of fee payment: 10
2025-07-25	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: TR Payment date: 20250428 Year of fee payment: 10 Ref country code: SK Payment date: 20250429 Year of fee payment: 10
2025-07-28	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: CZ Payment date: 20250429 Year of fee payment: 10
2025-07-29	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: IE Payment date: 20250424 Year of fee payment: 10
2025-07-30	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: SE Payment date: 20250423 Year of fee payment: 10 Ref country code: SI Payment date: 20250429 Year of fee payment: 10
2025-11-11	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: MK Payment date: 20250428 Year of fee payment: 10
2026-01-20	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: CY Payment date: 20250424 Year of fee payment: 10
2026-03-15	REG	Reference to a national code	Ref country code: AT Ref legal event code: UEP Ref document number: 1621810 Country of ref document: AT Kind code of ref document: T Effective date: 20231018

Publication	Publication Date	Title
PL3294345T3 (pl)	2024-07-01	Formulacje tpp1 i sposoby leczenia choroby cln2
EP3490582A4 (fr)	2020-04-01	Méthodes et compositions de traitement de maladie.
EP3607072A4 (fr)	2021-01-06	Compositions et méthodes de traitement de la phénylcétonurie
EP3515505A4 (fr)	2020-04-22	Traitement vaa de la maladie de huntington
EP3645121A4 (fr)	2021-03-17	Méthodes de traitement de la maladie de huntington
EP3458589A4 (fr)	2020-01-01	Compositions et méthodes de traitement de la maladie de huntington
EP3813808A4 (fr)	2022-01-26	Méthodes de traitement de la toxicomanie
EP3397149A4 (fr)	2019-08-14	Cartographie et traitement de tissu
EP3291815A4 (fr)	2019-01-16	Méthodes de traitement d'une maladie neurodégénérative
EP2981551A4 (fr)	2016-11-09	Méthodes et compositions pour le traitement de la maladie de pompe
EP3261641A4 (fr)	2019-05-22	Traitement de la pancréatite
EP2854839A4 (fr)	2015-11-25	Méthodes de traitement de la maladie c liaque
MA41115A (fr)	2017-10-10	Procédé de traitement de la maladie d'alzheimer
MA45149A (fr)	2019-04-10	Méthodes de traitement de la maladie d'alzheimer
MA48730A (fr)	2020-04-08	Compositions et méthodes de traitement de synucléinopathies
EP3519058C0 (fr)	2023-06-07	Compositions et méthodes de traitement des cheveux
PL3277270T3 (pl)	2022-02-14	Kompozycje i sposoby leczenia niedokrwistości
EP3600285A4 (fr)	2021-01-13	Compositions topiques et méthodes de traitement
EP3658142A4 (fr)	2021-06-09	Compositions et méthodes de traitement de la galactosémie
FR3034011B1 (fr)	2018-05-18	Procede de traitement cosmetique des cheveux
EP3599983A4 (fr)	2021-01-06	Endoscopes et méthodes de traitement
EP3727452A4 (fr)	2021-09-22	Compositions et méthodes de traitement de la néoplasie
EP3546449A4 (fr)	2020-06-10	Dérivé de pipéridine -2,6-dicétone et traitement de la maladie de crohn
MA45245A (fr)	2019-04-17	Méthode de traitement de maladie intestinale inflammatoire
EP3352729A4 (fr)	2019-06-19	Méthodes et compositions de traitement de la peau